1203 Kinnate IPO
BioCentury & Getty Images

Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

Shares nearly double in first day of trading

Oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on the exchange this year, building upon a record.

Dec 4, 2020 | 1:24 AM GMT

Two years after its launch, precision oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on NASDAQ

Read the full 745 word article

How to gain access

Continue reading with a
two-week free trial.